Use and Uptake of Newer Narcolepsy Treatments in Clinical Practice


Drs Thorpy, Dogan, Doghramji, and Kushida talk about the use and uptake of newer narcolepsy treatments in clinical practice.

This is a video synopsis/summary of a panel discussion involving Michael Thorpy, MD; Karl Doghramji, MD, FAASM, DFAPA; Clete Kushida, MD, PhD; and Richard K Bogan, MD.

Experts discusses the long-term safety and effectiveness of various medications used for narcolepsy treatment. Studies, lasting up to 12 months, have shown that medications like pitolisant, solriamfetol, and sodium oxybate are safe and effective over extended periods. Additionally, open-label extension studies have confirmed the continued safety and efficacy of these medications beyond the initial study periods.

The conversation then shifts to the impact of newer medications on narcolepsy treatment. Polypharmacy, the use of multiple medications, is common due to concerns about tolerance, rebound, and withdrawal, particularly with schedule 2 drugs. The approach to treatment involves tailoring medication regimens to individual patient needs, considering factors such as comorbidities, mood, and response to treatment. Polypharmacy is seen as an important aspect of managing narcolepsy effectively, with adjustments made based on ongoing assessment of symptoms and quality of life. Overall, treatment is viewed as a continuum rather than a 1-time prescription, emphasizing the need for personalized and flexible approaches.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.

Related Videos
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
© 2024 MJH Life Sciences

All rights reserved.